These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 12706711)
1. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting". Leverone JF; Spooner ET; Lehman HK; Clements JD; Lemere CA Vaccine; 2003 May; 21(17-18):2197-206. PubMed ID: 12706711 [TBL] [Abstract][Full Text] [Related]
2. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644 [TBL] [Abstract][Full Text] [Related]
3. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Lemere CA; Spooner ET; Leverone JF; Mori C; Clements JD Neurobiol Aging; 2002; 23(6):991-1000. PubMed ID: 12470794 [TBL] [Abstract][Full Text] [Related]
4. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Kim HD; Jin JJ; Maxwell JA; Fukuchi K Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533 [TBL] [Abstract][Full Text] [Related]
6. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Maier M; Seabrook TJ; Lemere CA Vaccine; 2005 Oct; 23(44):5149-59. PubMed ID: 16054274 [TBL] [Abstract][Full Text] [Related]
7. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Seabrook TJ; Thomas K; Jiang L; Bloom J; Spooner E; Maier M; Bitan G; Lemere CA Neurobiol Aging; 2007 Jun; 28(6):813-23. PubMed ID: 16725229 [TBL] [Abstract][Full Text] [Related]
8. The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol. Spooner ET; Desai RV; Mori C; Leverone JF; Lemere CA Vaccine; 2002 Dec; 21(3-4):290-7. PubMed ID: 12450704 [TBL] [Abstract][Full Text] [Related]
9. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Lemere CA Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650 [TBL] [Abstract][Full Text] [Related]
10. Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Town T; Tan J; Sansone N; Obregon D; Klein T; Mullan M Neurosci Lett; 2001 Jul; 307(2):101-4. PubMed ID: 11427310 [TBL] [Abstract][Full Text] [Related]
11. MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice. Liu B; Frost JL; Sun J; Fu H; Grimes S; Blackburn P; Lemere CA J Neurosci; 2013 Apr; 33(16):7027-37. PubMed ID: 23595760 [TBL] [Abstract][Full Text] [Related]
12. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. Kim HD; Tahara K; Maxwell JA; Lalonde R; Fukuiwa T; Fujihashi K; Van Kampen KR; Kong FK; Tang DC; Fukuchi K J Gene Med; 2007 Feb; 9(2):88-98. PubMed ID: 17219449 [TBL] [Abstract][Full Text] [Related]
14. Norovirus P particle: an excellent vaccine platform for antibody production against Alzheimer's disease. Fu L; Li Y; Hu Y; Yu B; Zhang H; Wu J; Wu H; Yu X; Kong W Immunol Lett; 2015 Nov; 168(1):22-30. PubMed ID: 26349054 [TBL] [Abstract][Full Text] [Related]
15. Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. Seabrook TJ; Jiang L; Thomas K; Lemere CA J Neuroinflammation; 2006 Jun; 3():14. PubMed ID: 16753065 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's disease. Guan X; Yang J; Gu H; Zou J; Yao Z Hum Vaccin Immunother; 2013 Aug; 9(8):1643-53. PubMed ID: 23732905 [TBL] [Abstract][Full Text] [Related]
17. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Das P; Murphy MP; Younkin LH; Younkin SG; Golde TE Neurobiol Aging; 2001; 22(5):721-7. PubMed ID: 11705631 [TBL] [Abstract][Full Text] [Related]
18. A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease. Xing HY; Li B; Peng D; Wang CY; Wang GY; Li P; Le YY; Wang JM; Ye G; Chen JH PLoS One; 2017; 12(6):e0180076. PubMed ID: 28662102 [TBL] [Abstract][Full Text] [Related]
19. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice. Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663 [TBL] [Abstract][Full Text] [Related]
20. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. Das P; Howard V; Loosbrock N; Dickson D; Murphy MP; Golde TE J Neurosci; 2003 Sep; 23(24):8532-8. PubMed ID: 13679422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]